Navigation Links
VYVANSE provided behavior, inattention and math test score improvements in children with ADHD
Date:10/29/2008

CHICAGO October 29, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a 13-hour analog classroom study in school-aged children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD). In this study, researchers found that VYVANSE controlled ADHD symptoms from the first time point measured (1.5 hours) through the last time point assessed (13 hours) post-dose. Findings from this analog classroom study were presented today at a national psychiatric meeting in Chicago.

"The study presented today is the first published data demonstrating improvements in attention and behavior with an oral ADHD stimulant treatment for up to 13 hours post-dose," said Ann C. Childress, MD, study investigator, president of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas, and volunteer assistant professor of psychiatry at the University of Nevada School of Medicine in Las Vegas. "In this study, once-daily VYVANSE significantly improved attention and behavior at 1.5 hours after a morning dose of the medication and continued to do so for each time point measured throughout the 13-hour treatment day. These findings are significant because children with ADHD require symptom control that lasts throughout the school day as well as after-school hours."

This study confirms the results of a previous clinical trial in which VYVANSE demonstrated ADHD symptom control throughout a 12-hour treatment day. The adverse events in the 12-hour study for patients taking Vyvanse during the double-blind treatment period that were greater than or equal to 2 percent were insomnia, decreased appetite, and anorexia.

"This is encouraging news for physicians and patients seeking a long-acting ADHD treatment option as this study demonstrated symptom control during a 13-hour treatment day," said Mike Cola, President of Shire's Specialty Pharmaceuticals business. "This VYVANSE st
'/>"/>

Contact: Jacelyn Seng
212-601-8385
Porter Novelli
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Phase III pivotal results presented of VYVANSE to treat ADHD in adults
2. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
3. FDA approves additional dosage strengths of Vyvanse
4. Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track
5. VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
6. Hissey Kientz Concerned That Patients Have Not Been Provided With Crucial Information About Digitek Recall Despite the Dangers of Digoxin Toxicity
7. All Pets With Cancer in U.S. Provided Free Consultation
8. NABP Findings Underscore Dangers of Purchasing Prescription Medicine Online and From Foreign Sources
9. New National Medicaid Study Underscores Importance of Including State Relief in Stimulus Plan
10. Score Big With One-of-a-Kind Swarovski Encrusted SCRABBLE(R) Board
11. Local Experts Help Women Living and Working with Cancer Even the Score
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 1, 2014 (HealthDay News) -- Genes may interact with stress ... suggests. The genetic risk occurs in about 13 percent ... finding could help these people reduce their heart disease risk ... and stress management, the Duke University researchers said. The ... found a strong link between variations in the EBF1 gene ...
(Date:10/2/2014)... By Dennis Thompson ... -- A newborn,s risk of developing celiac disease isn,t reduced ... found in wheat called gluten to an infant,s diet help ... a pair of new studies in the Oct. 2 ... put to rest hopes that a child could avoid celiac ...
(Date:10/2/2014)... Dennis Thompson HealthDay ... Forty-two states and the District of Columbia now have a ... respiratory illness that has been infecting children since the ... with the virus have died in recent weeks, but it,s ... played in those deaths, officials said. Health officials are ...
(Date:10/1/2014)... small protein beta-amyloid is strongly associated with Alzheimer,s disease; ... this peptide is the causal agent of the onset ... such confirmation is that beta-amyloid is not harmful when ... is when it self-assembles to form the so-called amyloid ... target, beta-amyloid alone, but with multiple ones because each ...
(Date:10/1/2014)... human eye, the brain of a rat and a ... says a QUT leading robotics researcher. , Dr ... the new study uses new computer algorithms to enable ... tunnels. , "This is a very Frankenstein type of ... of a thing together because we,re taking the eyes ...
Breaking Medicine News(10 mins):Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2
... LeMond ... real-to-life road feel and performance output to ensure avid cyclists and triathletes stay in ... ... introduces the all-new Revolution bike trainer that delivers the industry,s most real-to-life ...
... ... get more exposure through free publicity and other low cost PR methods. , ... (PRWEB) July 2, 2010 -- ADPublishing.org LLC, ... guide which enables small business owners to generate their own free publicity. Online PR and ...
... ... C-rich , ... IL (PRWEB) July 2, 2010 -- There’s growing consumer awareness and concern in the U.S. ... children. This month (July 2010), European food and beverage manufacturers will be required to include ...
... routine for protection against infection when percutaneous endoscopic gastrostomy ... wall, is surgically inserted in the stomach. The new ... used today. The method, presented in the British ... 200 patients at the Karolinska University Hospital in Solna, ...
... ... Northwestern Health Sciences University to create an experienced team of chiropractic and medical professionals ... years old). , ... (PRWEB) July 2, 2010 -- University of Western States has partnered with Northwestern Health ...
... ... Templar cross architecture contains math codes that support frequency-based medicine. The idea ... paradigm that will change the face of future medicine. , ... (PRWEB) July 2, 2010 -- It usually ...
Cached Medicine News:Health News:As Real as It Gets: All-New LeMond Revolution Bike Trainer Delivers Incomparable Road Feel and Performance 2Health News:As Real as It Gets: All-New LeMond Revolution Bike Trainer Delivers Incomparable Road Feel and Performance 3Health News:Publishing and Media Distribution Firm Launches Online Public Relations Kit for Businesses Seeking Free Publicity 2Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 2Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 3Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 4Health News:Simpler and cheaper antibiotic prophylaxis with insertion of nutrition catheter in the stomach 2Health News:Study Seeks Effective Treatment for Adolescent Low Back Pain 2Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 2Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 3Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 4Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 5
(Date:10/2/2014)... , Oct. 2, 2014   Mast Therapeutics, ... announced today that Edwin L. Parsley , D.O. ... and Senior Vice President.  Dr. Parsley has ... Aires Pharmaceuticals, Inc. in February 2014.  He has served ... and as Chief Medical Officer of Aires since April ...
(Date:10/2/2014)...   Intarcia Therapeutics, Inc. today announced successful ... clinical trials for ITCA 650 (exenatide, delivered continuously once ... The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase ... of ITCA 650 in patients with type 2 diabetes ... significantly superior to placebo for both 40 mcg and ...
(Date:10/1/2014)...   Plexus Information Systems, Inc. (Plexus ... Systems (AIMS), announced a partnership with NextGen ... subsidiary of Quality Systems, Inc. and a leading ... Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product portfolio ...
Breaking Medicine Technology:Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
... Feb. 9, 2011 Reportlinker.com announces that ... in its catalogue: Global ... Plaque Treatment 2011 ... the responses of a comprehensive survey conducted ...
... 9, 2011 Reportlinker.com announces that a new ... Asia Pacific Markets for Orthopedic ... http://www.reportlinker.com/p0377965/Asia-Pacific-Markets-for-Orthopedic-Large-Joint-Reconstructive-Devices-2011.html In 2010, the ... Japan and South Korea were valued at over ...
Cached Medicine Technology:Reportlinker Adds Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011 2Reportlinker Adds Asia Pacific Markets for Orthopedic Large Joint Reconstructive Devices 2011 2
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
Medicine Products: